This post-hoc analysis used a combined cohort of 509 patients with RET-mutated advanced or metastatic medullary thyroid cancer who had received selpercatinib in the two trials. Hadoux reported that ...
Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.
Ozempic, a drug initially used to treat type 2 diabetes, is gaining attention for its weight loss benefits and potential to reduce Alzheimer's risk. However, it comes with side effects like nausea, ...